Is AI the Prescription for Better Health Care?

What This Video Is About

This video discusses the role of AI in healthcare, its potential benefits and challenges, and the investment opportunities and risks associated with it. Ellen Zentner, Chief Economic Strategist at Morgan Stanley Wealth Management, provides insights into the current state of drug research, the potential of AI in healthcare, and the key considerations for investors.

Major Ideas Discussed

• AI has made generating scientific ideas cheaper, but proving those ideas work in patients remains difficult and expensive.
• The US healthcare spending has reached $5.3 trillion in 2024, roughly 18% of GDP, despite drug research becoming less productive over the years.
• AI offers a credible path to improving the equation, with better models, richer data sets, and cheaper computing allowing researchers to identify promising drug candidates faster.
• However, investors should be careful about extrapolating early results, as a drug that clears safety testing still must demonstrate that it works in patients, navigate clinical trials, and secure reimbursement.
• AI can accelerate discovery without shortening the subsequent process, and cheaper discovery could increase total research spending as companies pursue more candidates.
• Laboratory and clinical trial capacity is already constrained, and the industry may find itself generating promising ideas faster than it can test them.
• Contract research organizations and scientific software providers could benefit as research activity expands.
• Large pharmaceutical companies hold valuable proprietary data sets that may become more important as AI advances.
• AI-native drug developers offer substantial upside potential, but a single clinical trial can still determine whether years of investment produce a commercially viable treatment.

What to Watch Next

The video suggests monitoring the development of AI applications in care delivery, including medical imaging, clinical documentation, and workflow tools, as well as the progress of contract research organizations, scientific software providers, and AI-native drug developers.